Filing Details

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Helius Medical Technologies, Inc. -------------------------------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------------------------------- (Title of Class of Securities) 42328V801 -------------------------------------------------------------------------------- (CUSIP Number) December 31, 2023 -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |_| Rule 13d-1(b) |X| Rule 13d-1(c) |_| Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

-------------------------------------------------------------------------------- CUSIP No. 42328V801 13G Page 2 of 5 Pages -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Columbus Capital Management, LLC 94-3262667 -------------------------------------------------------------------------------- 2. Check the Appropriate Box If a Member of a Group (See Instructions) (a) |_| (b) |_| -------------------------------------------------------------------------------- 3. SEC Use Only -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization California, USA -------------------------------------------------------------------------------- 5. SOLE VOTING POWER 50,000 shares of Common Stock and 20,116 warrants to purchase shares of Common Stock. (See Item 4) ------------------------------------------------------------- 6. SHARED VOTING POWER NUMBER OF SHARES 0 BENEFICIALLY ------------------------------------------------------------- OWNED BY EACH 7. SOLE DISPOSITIVE POWER REPORTING PERSON WITH 50,000 shares of Common Stock and 20,116 warrants to purchase shares of Common Stock. (See Item 4) ------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 0 -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 50,000 shares of Common Stock and 20,116 warrants to purchase shares of Common Stock. (See Item 4) -------------------------------------------------------------------------------- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) |_| -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row (9) 9.90% -------------------------------------------------------------------------------- 12. Type of Reporting Person (See Instructions) IA -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- CUSIP No. 42328V801 13G Page 3 of 5 Pages Item 1. (a) Name of Issuer: Helius Medical Technologies, Inc. (b) Address of Issuer's Principal Executive Offices: 642 Newtown Yardley Road, Suite 100, Newtown, PA 18940 Item 2. (a) Name of Person Filing: Columbus Capital Management, LLC (b) Address of the Principal Office or, if none, residence: 301 E. Strawberry Drive, Mill Valley, CA 94941 (c) Citizenship: California, USA (d) Title of Class of Securities: Common Stock (e) CUSIP Number: 42328V801 Item 3. If this statement is filed pursuant to SS.240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) |_| Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) |_| Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) |_| Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) |_| Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). (e) | | An investment adviser in accordance with S.240.13d-1(b)(1)(ii)(E); (f) |_| An employee benefit plan or endowment fund in accordance with S.240.13d-1(b)(1)(ii)(F); (g) |_| A parent holding company or control person in accordance with S. 240.13d-1(b)(1)(ii)(G); (h) |_| A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) |_| A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) |_| Group, in accordance with S.240.13d-1(b)(1)(ii)(J). -------------------------------------------------------------------------------- CUSIP No. 42328V801 13G Page 4 of 5 Pages Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 50,000 shares of Common Stock and 20,116 warrants to purchase shares of Common Stock. (b) Percent of class: 9.90% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 50,000 shares of Common Stock and 20,116 warrants to purchase shares of Common Stock. (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 50,000 shares of Common Stock and 20,116 warrants to purchase shares of Common Stock. Pursuant to the terms of the reported warrants, the Reporting Person cannot exercise any of the warrants if the Reporting Person would beneficially own, after such exercise, more than 9.90% of the outstanding shares of Common Stock ("the 9.90% Blocker"). Consequently, at this time, the Reporting Person is not able to exercise all warrants due to the 9.90% Blocker. The percentage set forth in Row (11) of the cover page for the Reporting Person gives effect to the 9.90% Blocker. Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following |_|. Item 6. Ownership of More than Five Percent on Behalf of Another Person. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. Item 8. Identification and Classification of Members of the Group Item 9. Notice of Dissolution of Group -------------------------------------------------------------------------------- CUSIP No. 42328V801 13G Page 5 of 5 Pages Item 10. Certification (a) The following certification shall be included if the statement is filed pursuant to S.240.13d-1(b): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect (b) The following certification shall be included if the statement is filed pursuant to S.240.13d-1(c): By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 02/13/2024 ------------------------------------------- Date /s/ David S. Proskin ------------------------------------------- Signature David S. Proskin, Chief Financial Officer ------------------------------------------- Name/Title